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External pituitary irradiation (XRT) has been used as a thera-
peutic modality in patients with acromegaly for the past 100
years. Multiple studies have demonstrated the slow but inexorable
decline of plasma GH for as long as 20–25 years after the
procedure, with some 70–90% of patients ultimately achieving








g = 2·6 mU). Also, XRT
either shrinks pituitary tumours or, at the very least, effectively
prevents them from enlarging. Thus, XRT offers both biochem-
ical and morphological benefits to patients with acromegaly.
However, the downside of XRT is not negligible. Up to 50–60%
of patients develop hypopituitarism, and some have optic nerve
damage or ophthalmoplegia. The ensuing cerebrovascular
damage raises the risk of a cerebrovascular accident 2–4-fold.
Additionally, there is a small (1–2%) but devastating risk of
developing radiation-induced malignant brain tumours, and the
neurocognitive impairments (memory deficits, depression,
etc.) appear to be significant. The morbidities of acromegaly
(arthropathy, cardiomyopathy, sleep apnea, etc.) also continue
to progress during the long interval between the procedure and
the biochemical ‘cure’. Despite these problems, the balance
between the risks and benefits of XRT was clearly tilted towards
the latter as long as surgical techniques remained crude and the
pharmacological modalities nonexistent. Most importantly, the




g / l were biologically harmless
(Christy, 1982) implied that radiotherapy was a highly effective
therapeutic modality.
The development and wide availability of IGF-1 assays have
changed the definition of what constitutes good control of
acromegaly. On purely theoretical grounds, measurement of a
trophic, instead of a target, hormone seems to be misplaced.
Indeed, one would not claim ‘cure’ of Cushing’s disease or a
TSH-producing tumour based on ‘normal’ ACTH or TSH con-
centrations as long as cortisol or thyroxine levels remain elevated.
Clinical manifestations of acromegaly correlate very well with





1979). Plasma IGF-1 remains elevated in 10–40% of the patients













., 2001), and the mortality in such patients is








., 1998) despite statistical ‘similarity’ with the general
population. Even newly diagnosed and clinically active patients
may present with a full-blown clinical picture of acromegaly despite





., 1999). Finally, the recent data on the GH
receptor antagonist, pegvisomant, proved beyond a doubt that
normalization of plasma IGF-1 leads to a dramatic improvement





These considerations led to the virtually universal acceptance of
plasma IGF-1 as the most appropriate and accurate index of
disease control.
How efficacious is XRT when measured according to this
parameter? The reported percentages of IGF-1 normalization
vary widely between studies due to inhomogeneity and the
limited size of the study groups, the variable durations of follow-
up, and the use of different IGF-1 assays. Fortunately, the tech-
nique of XRT is almost standard around the world and, unlike
surgery, is largely operator independent. The meta-analytical
approach compensates for the heterogeneity of patient popula-
tions in different studies and smoothes the fluctuation in the
outcomes. However, many, if not most, of the published series do
not provide individual data and use either mean or median follow-
up as a time frame. This introduces an additional level of diffi-
culty in interpreting the ‘summed-up’ data, especially when they
are related to the time course of normalization of hormone
parameters.
In Table 1, data are summarized from all but two of the
published series reporting the efficacy of XRT in terms of IGF-1
normalization in acromegaly, including a personal communication
from Dr Philippe Jaquet from Marseille. Two studies were not





80% of the allegedly normal IGF-1 values were accompanied




g / l, casting
grave doubt on the validity of the IGF-1 assay employed in that





than a third of the patients prior to XRT had plasma IGF-1 levels
overlapping the normal range, and another third did not have
IGF-1 measured before XRT but were found to have normal
IGF-1 values at the very first post-XRT follow-up within 2 years.
Thus, many, or perhaps most, patients in that study had normal
IGF-1 because of curative surgery rather than XRT.
The overall frequency of normalization of IGF-1 after conven-
tional XRT was 36%. In the series with a duration of either mean
or median follow-up less than 7 years, the efficacy was 29% (61
of 210) and in those with follow-up longer than 10 years it rose
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to 39% (138 of 350). However, the number of patients lost to
follow-up increases significantly with time in all published series,
and those followed for 15–20 years usually constitute about 10%
of the total number, limiting the reliability of the analysis. More
importantly, poorly controlled patients are more likely to die
prematurely, leaving the ‘cured’ ones available for a long-term
analysis, thus providing a skewed and falsely optimistic impres-
sion of the long-term efficacy of XRT.
What about the relatively new modality of stereotactic radio-
surgery (SRS)? Its theoretical advantage over conventional XRT
is the ability to deliver a very large dose of radiation to a sharply
defined area in a single treatment. However, analysis of the old





. (1990) reported results of low-dose conven-















g/l were reached in 26% and 30% after 5 years and
in 49% and 53% after 10 years in the two series, respectively.
Even though there are differences in the radiobiology of the two
modalities, the identical outcomes do not support the notion of




. (1989) provided the only available





beam technique in small numbers of patients. After 5 years of





in 47% of the former and 38% of the latter group, an almost
identical result. Table 2 summarizes all the available reports of
the gamma-knife or linear accelerator techniques that used IGF-
1 as the efficacy parameter.
Overall, only 33% of patients achieved normal IGF-1 levels




 SRS) one has to take into account the shorter follow-up in
the latter series. Including only the series with a mean or median
follow-up between 2 and 10 years (to provide maximal advantage
to the SRS data), 33% of the patients in the SRS series (77 of
232) and 29% after XRT (99 of 341) achieved the goal of a
normal IGF-1, again an almost identical number. Some authors





2000) have mentioned that normalization of IGF-1 in their
‘responders’ occurred faster than what would have been expected
had XRT been used instead. This clinical impression is intriguing
but requires additional studies for objective confirmation. Speed




 XRT does not seem
to be supported by the existing data. Local toxicities of SRS also
have to be taken into account; for example, ophthalmoplegia and

















., 2001) occur much
more often with SRS than with XRT.
Thus, the efficacy of radiation therapy, when judged by the
strict criterion of normalization of IGF-1, is significantly less
than was reported in the past when success was measured by GH
levels. The existing data on SRS fail to confirm its higher efficacy
compared with conventional XRT. The introduction of modern
pharmacological compounds, somatostatin analogues in particu-
lar, also weakened the argument for the use of XRT as a ‘tumour
shrinking’ modality, as these drugs not only normalize plasma
IGF-1 in the majority of patients but also effectively prevent
tumour regrowth for as long as they are administered. The immin-
ent introduction of the GH receptor antagonist, pegvisomant,
more or less assures normalization of IGF-1 in every patient.
Thus, both biochemical and morphological goals of therapy can
be achieved pharmacologically without exposing the patients to
increased risks of hypopituitarism, vascular damage, blindness,
ophthalmoplegia and secondary tumour formation, which are
part and parcel of radiation therapies.








Giannella-Neto et al. (1988) 5 8 2
Barkan et al. (1997) 6·8 38 2
Van der Lely et al. (1997) 7 37 0
Thalassinos et al. (1998) > 10 14 4
Swearingen et al. (1998) 6·7 45 19
Powell et al. (2000) 5·2 31 14
Barrande et al. (2000) 15 47 37
Bezerra et al. (2000) 4 51 20
Alfaro et al. (2000) 10 91 38
Gutt et al. (2001) 12·8 41 14
Cozzi et al. (2001) 14 49 8
Epaminonda et al. (2001) 12 67 37
Jaquet (pers. commun.) 7 40 4
Total 560 199








Voges et al. (1996) > 0·5 14 0
Mokry et al. (1999)  4 16 4
Laws and Vance (1999)  0·5–9 36 9
Kim et al. (1999)  1 2 0
Jackson and Noren (1999)  1–4 10 6
Vladyka et al. (2000) 2 91 39
Powell (2000) 5 10 3
Landolt et al. (2000) 0·5–2·5 31 13
Shin et al. (2000)   3 6 4
Barausse et al. (2001) 11 9 1
Epaminonda (2001) 4 16 3

















The use of radiotherapy may still be justified in patients whose
tumours are unresponsive to somatostatin and continue to grow.
In societies with limited health budgets, new and expensive drugs
are likely to be unaffordable and radiation may remain the only
available alternative. One can also argue that radiation may allow
eventual termination of drug therapy in a subset of patients, and
a medico-economic analysis of such an approach may be useful.
Accurate knowledge of the true efficacy of radiation therapy is
needed for a realistic approach to all these quandaries.
In summary, the widespread use of radiotherapy in the past
was due to a lack of other, more effective therapies such as
sophisticated surgical techniques and pharmacological prepara-
tions. Its supposedly high efficacy was asserted on the basis of




g / l range
had no appreciable deleterious effects (Christy, 1982). Recent
developments in imaging and surgical techniques allow us to
detect the presence or regrowth of a pituitary tumour with accur-
acy and to remove it with a high degree of precision and success.
Novel pharmacological preparations reliably prevent tumour
regrowth and are capable of normalizing plasma IGF-1, the real
culprit of the clinical syndrome, in almost all surgically uncured
cases. Thus, the era of the indiscriminate use of radiotherapy in
acromegaly has come to an end.
About 2500 years ago, Hippocrates formulated a therapeutic
dictum: ‘What drugs do not cure, that the knife cures. What knife
doesn’t cure, that the fire cures. What fire doesn’t cure, must
be called incurable.’ In patients with acromegaly, radiation, the
modern equivalent of Hippocratic fire, should now assume its
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